Effects of four antiplatelet/statin combined strategies on immune and inflammatory responses in patients with acute myocardial infarction undergoing pharmacoinvasive strategy: Design and rationale of the B and T Types of Lymphocytes Evaluation in Acute Myocardial Infarction (BATTLE-AMI) study: study protocol for a randomized controlled trial

Fonseca, Francisco Antônio Helfenstein; Izar, Maria Cristina; Maugéri, Ieda Maria Longo; Berwanger, Otávio; Damiani, Lucas Petri; Pinto, Ibraim Masciarelli Francisco; Szarf, Gilberto; França, Carolina Nunes; Bianco, Henrique Tria; Moreira, Flávio Tocci; Caixeta, Adriano; Alves, Cláudia Maria Rodrigues; Lopes, Aline Soriano; Klassen, Aline; Tavares, Marina Franco Maggi; Fonseca, Henrique Andrade Rodrigues da; Carvalho, Antônio Carlos

doi:10.1186/s13063-017-2361-1

Cited by 18 publications

(22 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For the present study, 120 consecutive adults of both sexes with their first myocardial infarction were included in the B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction (BATTLE-AMI study, NCT02428374) [ 9 ]. Figure 2 shows the total number of patients assessed, enrolled and that completed the trial.…”

Section: Methodsmentioning

confidence: 99%

“…Cardiac MRI was performed at the 30th day after STEMI as previously reported [ 9 ], based on previous cMRI sequencial studies since baseline, reporting changes, at 30 and 180 days, in the strain of the peri-infarction myocardial or in the infarcted mass, and to explore effects of inflammatory variables during the recovery and healing of myocardial infarction [ 10–12 ]. Briefly, images were performed on 3.0 T scanners and protocol included steady-state free precession imaging (SSFP) for anatomical evaluation, retrospective cine imaging in long and short axis views and late contrast-enhanced imaging using gadolinium for evaluation of myocardium scar/fibrosis.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Role of B lymphocytes in the infarcted mass in patients with acute myocardial infarction

et al. 2021

Self Cite

View full text Add to dashboard Cite

Despite early reperfusion, patients with ST segment elevation myocardial infarction (STEMI) may present large myocardial necrosis and significant impairment of ventricular function. The present study aimed to evaluate the role of subtypes of B lymphocytes and related cytokines in the infarcted mass and left ventricular ejection fraction obtained by cardiac magnetic resonance imaging performed after 30 days of STEMI. This prospective study included 120 subjects with STEMI submitted to pharmacoinvasive strategy. Blood samples were collected in subjects in the first (D1) and 30th (D30) days post STEMI. The amount of CD11b+ B1 lymphocytes (cells/ml) at D1 were related to the infarcted mass (rho = 0.43; P=0.033), measured by cardiac MRI at D30. These B1 cells were associated with CD4+ T lymphocytes at D1 and D30, while B2 classic lymphocytes at day 30 were related to left ventricular ejection fraction (LVEF). Higher titers of circulating IL-4 and IL-10 were observed at D30 versus D1 (P=0.013 and P<0.001, respectively). Titers of IL-6 at D1 were associated with infarcted mass (rho = 0.41, P<0.001) and inversely related to LVEF (rho = −0.38, P<0.001). After multiple linear regression analysis, high-sensitivity troponin T and IL-6 collected at day 1 were independent predictors of infarcted mass and, at day 30, only HDL-C. Regarding LVEF, high-sensitivity troponin T and high-sensitivity C-reactive protein were independent predictors at day 1, and B2 classic lymphocytes, at day 30. In subjects with STEMI, despite early reperfusion, the amount of infarcted mass and ventricular performance were related to inflammatory responses triggered by circulating B lymphocytes.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Role of B lymphocytes in the infarcted mass in patients with acute myocardial infarction

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Table S1 shows main characteristics of study population. The cohort is part of the B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction (BATTLE-AMI) study 39 (ClinicalTrials.gov, NCT02428374, registered on 28/09/2014). They had no prior MI and were naive for lipid-lowering treatment.…”

Section: Cohortmentioning

confidence: 99%

“…Key exclusion criteria included hemodynamic instability, autoimune disease, known malignancy, pregnancy and signs of active infections. The same sample size of the BATTLE-AMI trial was previsouly published 39 and, for this sub analysis, a convenient sample was used. The study protocol was approved by the local ethics committee (Escola Paulista de Medicina -UNIFESP IRB 0297/2014; CAAE: 71652417.3.0000.5505), which follows the Declaration of Helsinki, and written informed consent was provided by all subjects before their inclusion.…”

Section: Cohortmentioning

confidence: 99%

Evaluation of Two Highly Effective Lipid-Lowering Therapies in Subjects With Acute Myocardial Infarction: A Lipidomic Analysis

Klassen

Sussulini

Derogis

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Introduction For cardiovascular disease prevention, statins alone or combined with ezetimibe have been recommended to achieve low density lipoprotein - cholesterol targets, but their effects on other lipids are less reported. Objective To examine lipid changes in subjects with ST-segment elevation myocardial infarction (STEMI) after two highly effective lipid-lowering therapies. Methods Twenty patients with STEMI were randomized to be treated with rosuvastatin 20 mg qd or simvastatin 40 mg combined with ezetimibe 10 mg qd during 30 days. Fasting blood samples were collected in the first day (D1) and after 30 days (D30). Lipidomic analysis was performed using the Lipidyzer platform. Selected reaction monitoring (SRM) was used in positive and negative ionization modes with and without differential mobility spectrometry (DMS). Univariate and multivariate analyses were performed. Results Comparable classic lipid profile was observed in both groups of lipid-lowering therapies at D1 and after treatments. However, differences in other lipids were observed between groups at these time points. After treatments, main differences between groups were for lysophosphatidylcholine and triacylglycerides. Conclusion Despite similar changes in the classic lipid profile, differences in lipidomic analysis were found before and after exposure to highly effective lipid-lowering therapies in subjects after STEMI. Trial registration: ClinicalTrials.gov, NCT02428374, registered on 28/09/2014.

show abstract

“…At present, the commonly used diagnostic indicators for evaluating inflammatory response in myocardial infarction include erythrocyte sedimentation rate (ESR), white blood cell (WBC) count, and high-sensitivity C-reactive protein (hs-CRP) ( 7 – 9 ). However, these diagnostic indicators have disadvantages and limitations such as strict requirement in sample collecting time, low sensitivity, poor specificity, easy contamination, antibiotic interference, high cost, and long waiting time, suggesting that they are not appropriate to be used for diagnosis of myocardial infarction complicated by pulmonary infection ( 10 – 12 ).…”

Section: Introductionmentioning

confidence: 99%

Clinical study of serum procalcitonin level in patients with myocardial infarction complicated by pulmonary infection

Sun

Wang

et al. 2018

Exp Ther Med

View full text Add to dashboard Cite

This study determined the serum procalcitonin (PCT) levels in patients with myocardial infarction complicated by pulmonary infection and explore its clinical significance and diagnostic value. A total of 473 patients who were admitted to the Third Affiliated Hospital of Qiqihar Medical University from January 2016 to June 2017 were enrolled as research subjects. Patients were divided into four groups based on their symptom status in myocardial infarction and pulmonary infection. There were 109 patients in normal control group who did not experience symptoms of either myocardial infarction or pulmonary infection. Blood samples were collected from each patient, and PCT levels were measured. The data were analyzed. The serum PCT levels prior to treatment were compared with each other. The PCT levels in the myocardial infarction and the pulmonary infection group were all higher than that in the normal control group (0.040±0.015) (p<0.05). On the contrary, the serum PCT level in the myocardial infarction complicated by pulmonary infection group was higher than that in the normal control group (p<0.001). The serum PCT level after treatment was compared with that before treatment within the same group. The serum PCT levels in the three disease groups were comparable after treatment. The differences in PCT levels before and after treatment were all statistically significant within all three groups (p<0.05). A patient's serum PCT level was correlated with myocardial infarction complicated by pulmonary infection, which suggested it can be used as an important diagnostic marker for this complication. This finding has important clinical value for predicting and evaluating the complicated condition of myocardial infarction and pulmonary infection by providing a more accurate, sensitive, and specific method for early diagnosis of the disease.

show abstract

Cited by 18 publications

References 33 publications

Role of B lymphocytes in the infarcted mass in patients with acute myocardial infarction

Role of B lymphocytes in the infarcted mass in patients with acute myocardial infarction

Evaluation of Two Highly Effective Lipid-Lowering Therapies in Subjects With Acute Myocardial Infarction: A Lipidomic Analysis

Clinical study of serum procalcitonin level in patients with myocardial infarction complicated by pulmonary infection

Contact Info

Product

Resources

About